The last two decades have seen a surge in antimalarial drug development with product
development partnerships taking a leading role. Resistance of Plasmodium falciparum to the …

Increased efforts in antimalarial drug discovery are urgently needed. The goal must be to
develop safe and affordable new drugs to counter the spread of malaria parasites that are …

Discovery of a relict chloroplast (the apicoplast) in malarial parasites presented new
opportunities for drug development. The apicoplast–although no longer photosynthetic–is …

Approximately 40% of the world population live in areas with the risk of malaria. Each year,
300–500 million people suffer from acute malaria, and 0.5–2.5 million die from the disease …

Natural products containing carbon-phosphorus bonds (phosphonic and phosphinic acids)
have found widespread use in medicine and agriculture. Recent years have seen a …

The field of bacterial phosphorus (P) metabolism has undergone a significant transformation
in the past decade owing to the elucidation of widespread and diverse pathways for the …

Multidrug resistance has rendered monotherapy for malaria useless in most parts of the
world, and has also compromised the usefulness of many of the available combination …

The mitochondrion of Plasmodium species is a validated drug target. However, very little is
known about the functions of this organelle. In this review, we utilize data available from the …

Recently, considerable interest has developed regarding the presence of pharmaceuticals
in the environment, but as yet the potential ecological effects associated with the presence of …

2-C-Methyl-d-erythritol 4-phosphate synthase (IspC) is the first enzyme committed to
isoprenoid biosynthesis in the methylerythritol phosphate pathway, which represents an …